Jay Lieberman, MD

In part 2, Lieberman discusses why caregivers hesitate to use epinephrine and what system-level changes could close the gap in infants and toddlers.

New reviews outline barriers to epinephrine use and support age-specific anaphylaxis recognition criteria in infants and toddlers, says Jay Lieberman, MD.

At RAD2026, Lieberman notes advances in immunology and systemic therapies that are reshaping the link between dermatology and allergy/immunology.

Lieberman, spoke at RAD 2026 about highlights from his session, ‘Connecting AD to Other Dermatologic Disorders and Related Comorbidities.'

Part 4 highlights how expanding epinephrine delivery options can reduce barriers, support earlier administration, and improve real-world anaphylaxis outcomes.

In this segment, experts emphasize the importance of giving an infant experiencing anaphylaxis epinephrine at whatever dose may be available rather than delaying treatment.

In the second part of the special report, panelists delink epinephrine use from mandatory emergency department visits.

In the opening segment of this special report, panelists discuss updated anaphylaxis guidelines and early management priorities.